We also analyzed LATS2 expression using public data from TCGA, and unfortunately, no significant difference was observed in the mRNA level of LATS2. In 2017, Wei et al. identified EHMT2 as a frequently upregulated histone methyltransferase in patients with HCC, which contributes to epigenetic silencing of tumor suppressor gene RARRES3 [43]. The gene discussed is LATS2; the disease is hepatocellular carcinoma.